- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01662687
Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in CINV (Chemotherapy-induced Nausea and Vomiting) Associated With the Administration of MEC (Moderately Emetogenic Chemotherapy)
Randomized Study of the Efficacy and Safety of Transdermal Granisetron Compared With Intravenous and Oral Agent in the Control of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy
Multicenter, randomized, open-label, paralled-group, active-controlled study. The study is to demonstrate non-inferiority of the Granisetron Transdermal Delivery System (GTDS) compared with the intravenous and oral Granisetron in the prevention of CINV associated with moderately emetogenic Chemotherapy.
Patients scheduled to receive the one cycle of a ME chemotherapy regimen administered for 1-4 days will attend a Screening Visit 2 to 28 days before start of ME chemotherapy. Eligible patients will be randomized to 1 of 2 treatment groups at the Randomization Visit (1 to 2 days prior to ME chemotherapy).
- Sancuso patch
- Kytril inj.+Kytril tab.
The patch will be applied 2days (48-24h) prior to first daily dose of the moderately emetogenic chemotherapy regimen and remain in place for 6 days. The patient will be assessed daily until 4days after first chemotherapy administration. Adverse Events (AEs) will be collected until 14 days after the final dose of IP. Non-serious AEs will be followed-up until 14 days after the final dose of IP. Serious adverse events will be followed-up until they are resolved, stable or until the patient is lost to follow-up.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Yun-Ae Eom, BS
- Phone Number: 82-2-6924-3157
- Email: yaeom@lgls.com
Study Locations
-
-
-
Seoul, Korea, Republic of
- Recruiting
- Samsung Medical Center
-
Contact:
- Jin Seok Ahn, MD, PhD
- Phone Number: 82-2-3410-3453
- Email: ajis@skku.edu
-
Principal Investigator:
- Jin Seok Ahn, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female aged over 20 yrs
- Histologically and/or cytologically proven cancer patients
- Eastern Cooperative Oncology Group performance status 0, 1, 2
- A cycle of moderately emetogenic chemotherapy(NCCN Guidelines)
- Life expectancy of ≥ 3 months
- Normal liver function and renal function(total bilirubin ≤ 1.5 ULN, AST/ALT ≤ 2.5 ULN, in case of liver metastases AST/ALT ≤ 5 ULN, serum creatinine ≤ 1.5 ULN) patients
- Patients who signed the informed consent form
Exclusion Criteria:
A. Previous History
- Hypersensitivity to adhesive plasters
- Contraindications to 5-HT3 receptor antagonists
- Any other relevant medical history (at the discretion of the investigator)
B. Concomitant Medical Condition
- Current alcohol, drug or medication abuse
- Currently pregnant or breast feeding women, including planning pregnancy
- Clinically relevant abnormal laboratory values (at the discretion of the investigator)
- Clinically relevant heart, hepatic, renal, infectious, neurological or psychiatric disorders, or any other major systemic illness (at the discretion of the investigator)
- Any cause for nausea and vomiting other than CINV
- Any episode of retching, vomiting or uncontrolled nausea in the 72 h period prior to the chemotherapy administration
- Clinically relevant abnormal ECG parameters (at the discretion of the investigator)
C. Concomitant Therapy/Medication
- Concomitant radiotherapy of total body, brain or upper abdomen within one week prior to the study entry or planned during the study
- Intake of medication to control the symptoms of a brain tumor, brain metastasis or seizure disorder or neuropathy (unless peripheral neuropathy at the discretion of the investigator)
- Patients using selective serotonin reuptake inhibitor (SSRI) antidepressants (unless a stable dose for the duration of the study)
- Receipt of a narcotic analgesics (acceptable at the discretion of the investigator)
- Receipt of any other clinical trial drug < 30 days before the study or during the study
- Scheduled to receive a neurokinin NK1 receptor antagonist, dopamine receptor antagonist or another 5-HT3 receptor antagonist at 72 h prior to the administration of the chemotherapy or scheduled to do those medication during chemotherapy duration
- Drugs known to increase the QTc interval (unless a stable dose for the duration of the study at the discretion of the investigator)
D. Other
- Patients unlikely to comply with the study protocol (at the discretion of the investigator), e.g. uncooperative attitude, inability to return for follow-up visits and unlikelihood of completing the study
- The patch adhesion level was not more than 50% on the day of chemotherapy or the patch was not attached within two days before the chemotherapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Sancuso patch
|
Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days. Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24 hours) prior to start of chemotherapy. |
ACTIVE_COMPARATOR: Kytril
|
Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days. Active Comparator arm:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The percentage of patients achieving Complete Response (CR) without rescue therapy from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen
Time Frame: from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen
|
from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The percentage of patients achieving Complete Response (CR)
Time Frame: overall (Day 1~4)
|
overall (Day 1~4)
|
|
The percentage of patients achieving Complete Control (CC) without rescue therapy from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen
Time Frame: from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen
|
from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen
|
|
The percentage of patients achieving Complete Control (CC)
Time Frame: overall (Day 1~4)
|
overall (Day 1~4)
|
|
severity of nausea
Time Frame: overall (Day 1~4)
|
overall (Day 1~4)
|
|
severity of vomiting
Time Frame: overall (Day 1~4)
|
overall (Day 1~4)
|
|
Frequency of nausea from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen
Time Frame: from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen
|
from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen
|
|
Frequency of vomiting from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen
Time Frame: from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen
|
from the first administration until 24h after the start of the last day's administration of the ME chemotherapy regimen
|
|
Patient's satisfaction with anti-emetic therapy (Changes from Baseline to Day 5)
Time Frame: from baseline to Day 5
|
The patient's response to anti-emetic therapy was assessed and recorded by patients at Visit 3 (Baseline) and Visit 7 (Day 5).
The patient was asked to evaluate his/her satisfaction with the control of nausea and vomiting by marking the FLI-E (Functional Living Index - Emesis) with vertical lines.
|
from baseline to Day 5
|
The percentage of patients achieving Complete Response (CR)
Time Frame: per day (Day 1, 2, 3, 4)
|
per day (Day 1, 2, 3, 4)
|
|
The percentage of patients achieving Complete Control (CC)
Time Frame: per day (Day 1, 2, 3, 4)
|
per day (Day 1, 2, 3, 4)
|
|
severity of nausea
Time Frame: per day (Day 1, 2, 3, 4)
|
per day (Day 1, 2, 3, 4)
|
|
severity of vomiting
Time Frame: per day (Day 1, 2, 3, 4)
|
per day (Day 1, 2, 3, 4)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tae Won Kim, MD, PhD, Asan Medical Center
- Principal Investigator: Dong Bok Shin, MD, PhD, Gachon University Gil Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LG-SCSCL002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chemotherapy-induced Acute or Delayed Nausea and Vomiting (CINV)
-
LG Life SciencesCompletedChemotherapy-induced Acute or Delayed Nausea and Vomiting (CINV)Korea, Republic of
-
Fudan UniversityNot yet recruitingChemotherapy-induced Nausea and Vomiting (CINV)
-
Fudan UniversityRecruitingChemotherapy-induced Nausea and Vomiting (CINV)China
-
Merck Sharp & Dohme LLCCompletedChemotherapy-Induced Nausea and Vomiting (CINV)
-
Helsinn Healthcare SACompletedChemotherapy-induced Nausea and Vomiting (CINV)United States, Russian Federation, Serbia, Ukraine
-
Merck Sharp & Dohme LLCCompletedChemotherapy-induced Nausea and Vomiting (CINV)
-
Merck Sharp & Dohme LLCCompletedChemotherapy-Induced Nausea and Vomiting (CINV)
-
Merck Sharp & Dohme LLCCompletedChemotherapy-Induced Nausea and Vomiting (CINV)
-
Heron TherapeuticsActive, not recruitingChemotherapy-Induced Nausea and Vomiting (CINV)United States
-
GlaxoSmithKlineCompletedChemotherapy-Induced Nausea and Vomiting | Nausea and Vomiting, Chemotherapy-InducedTaiwan, United States, Germany, Russian Federation, Spain, Ireland, Thailand, Hong Kong, Mexico, Philippines, Austria, Chile, Greece, Poland, Canada, Czech Republic, United Kingdom, Hungary, Pakistan, Slovakia, Singapore, Portugal, ... and more
Clinical Trials on Sancuso patch
-
Kyowa Kirin, Inc.PPDCompletedHealthy VolunteersUnited States
-
Indiana UniversityKyowa Kirin, Inc.Withdrawn
-
Prostrakan PharmaceuticalsCompletedPharmacokineticsUnited Kingdom
-
Coloplast A/SCompleted
-
Coloplast A/SCompleted
-
En Chu Kong HospitalCompleted
-
Tianjin Medical University Cancer Institute and...RecruitingChemotherapy-induced Nausea and VomitingChina
-
Prostrakan PharmaceuticalsCompleted
-
Fudan UniversityRecruitingChemotherapy-induced Nausea and Vomiting (CINV)China